In a mouse model of pancreatic cancer, CCR2 antagonists blocked the mobilization of CCR2-positive monocytes from bone marrow into tumors, thereby limiting TAM production and curbing tumor growth and metastasis 169. Here, CCR2 is linked to pancreatic neoplasm.